960 Eli Lilly and Company $LLY Shares Bought by Bosman Wealth Management LLC

Bosman Wealth Management LLC grew its stake in Eli Lilly and Company (NYSE:LLY) by 30.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 4,084 shares of the company’s stock after acquiring an additional 960 shares during the quarter. Eli Lilly and Company makes up approximately 2.9% of Bosman Wealth Management LLC’s holdings, making the stock its 10th biggest holding. Bosman Wealth Management LLC’s holdings in Eli Lilly and Company were worth $4,725,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Choreo LLC grew its position in Eli Lilly and Company by 2.2% during the 3rd quarter. Choreo LLC now owns 30,453 shares of the company’s stock worth $35,237,000 after acquiring an additional 655 shares during the last quarter. Livelsberger Financial Advisory acquired a new stake in Eli Lilly and Company during the 3rd quarter valued at $193,000. Fonville Wealth Management LLC increased its holdings in Eli Lilly and Company by 21.8% during the 3rd quarter. Fonville Wealth Management LLC now owns 358 shares of the company’s stock valued at $414,000 after purchasing an additional 64 shares in the last quarter. Elwood & Goetz Wealth Advisory Group LLC raised its position in Eli Lilly and Company by 4.0% in the 3rd quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 964 shares of the company’s stock valued at $1,116,000 after purchasing an additional 37 shares during the last quarter. Finally, Sage Rhino Capital LLC raised its position in Eli Lilly and Company by 0.6% in the 3rd quarter. Sage Rhino Capital LLC now owns 2,027 shares of the company’s stock valued at $2,345,000 after purchasing an additional 13 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 in the last quarter. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Trading Up 3.1%

Shares of LLY opened at $1,415.64 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 12-month low of $834.19 and a 12-month high of $1,449.68. The firm has a market capitalization of $1.33 trillion, a PE ratio of 45.95, a price-to-earnings-growth ratio of 1.78 and a beta of 0.46. The stock’s fifty day simple moving average is $1,197.72 and its 200-day simple moving average is $1,092.57.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 93.68% and a net margin of 31.90%. The firm’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same quarter last year, the business earned $7.02 earnings per share. As a group, research analysts predict that Eli Lilly and Company will post 35.18 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is currently 22.46%.

Analyst Upgrades and Downgrades

A number of research firms have commented on LLY. TD Cowen reissued a “buy” rating and issued a $1,250.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Truist Financial restated a “buy” rating and issued a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday. Berenberg Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target for the company in a report on Tuesday, September 15th. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Weiss Ratings lowered shares of Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,398.43.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.